Skip to content

Medical emergency? What to do

Inhaled insulin linked to lung cancer: Pfizer

3-RXPublished April 10, 20081 min read

Key points

  • Over the course of the clinical trials, Pfizer said 6 of the 4,740 Exubera-treated patients versus 1 of the 4,292 patients not treated with Exubera developed lung cancer.
  • The warning states all patients who developed lung cancer had a prior history of cigarette smoking and that there are too few cases to determine whether the development of lung cancer is related to Exubera use.
  • The warning label stemmed from an ongoing review of data from the Exubera clinical trial program and post-marketing experience by Pfizer and the U.S.
  • Since Pfizer's exit last year, Eli Lilly and Novo Nordisk also ended inhaled insulin development programs.

Clinical trials of the inhaled insulin product Exubera revealed an increase in the number of lung cancer patient, leading Nektar Therapeutics to end talks with potential partners to market the product, Pfizer Inc and Nektar said on Wednesday

Over the course of the clinical trials, Pfizer said 6 of the 4,740 Exubera-treated patients versus 1 of the 4,292 patients not treated with Exubera developed lung cancer. One lung cancer case was also found after Exubera reached the market.

Pfizer updated the Exubera labeling to include a warning with safety information about lung cancer cases found in patients who used Exubera, which U.S. regulators approved in January 2006.

The warning states all patients who developed lung cancer had a prior history of cigarette smoking and that there are too few cases to determine whether the development of lung cancer is related to Exubera use.

Pfizer said in October it would stop marketing Exubera, ending its involvement with a product once thought to have the potential of helping diabetics avoid needle sticks. Sales of Exubera have been negligible.

The warning label stemmed from an ongoing review of data from the Exubera clinical trial program and post-marketing experience by Pfizer and the U.S. Food and Drug Administration, Pfizer said.

Pfizer said it will be discussing the timing of marketing authorization withdrawals with regulatory agencies.

Since Pfizer's exit last year, Eli Lilly and Novo Nordisk also ended inhaled insulin development programs.

Nektar said it will cease all spending associated with its inhaled insulin programs and will not incur charges related to the event.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Cancer

2 views are better than 1 in 3-D breast screening

One view 3D breast screening (tomosynthesis) means less radiation dose and about five seconds less compression, but a study from Yale University, New Haven, CT, found that obtaining both views is necessary to help…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.